Nuo TherapeuticsAURX 33 Days Payable is 82.87 as of Mar. 2026, which is 91% below its 10-year median of 914.74. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.25 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Nuo Therapeutics ranks better than 50.99% on this metric.
The historical rank and industry rank for Nuo Therapeutics's Days Payable or its related term are showing as below:
AURX'
s Days Payable Range Over the Past 10 Years
Min: 109.07 Med: 914.74 Max: 8884.87
Current: 117.05
During the past 13 years, Nuo Therapeutics's highest Days Payable was 8884.87. The lowest was 109.07. And the median was 914.74.
AURX's Days Payable is ranked better than 50.99% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs AURX: 117.05
Nuo Therapeutics's Days Payable
declined
from Mar. 2025 (332.20) to Mar. 2026 (82.87).
It may suggest that Nuo Therapeuticsaccelerated paying its suppliers.
Nuo Therapeutics Days Payable Related Terms
Nuo Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Nuo Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuo Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Nuo Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics (AURX) has a Days Payable of 82.87 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nuo Therapeutics and its competitors. This is 91% below median its historical median of 914.74. Over the past decade, Nuo Therapeutics' Days Payable has ranged from 109.07 to 8,884.87. According to the industry distribution chart, Nuo Therapeutics ranks #345 out of 704 companies in the Biotechnology industry, placing it in the top 49%.
Is Nuo Therapeutics' Days Payable too high?
Nuo Therapeutics' current Days Payable of 82.87 is 91% below median its 10-year median of 914.74. Over the past 10 years, this metric has ranged from a low of 109.07 to a high of 8,884.87. The Biotechnology industry median Days Payable is 113.56. Nuo Therapeutics' value of 82.87 is 27% below this industry median. Based on the distribution chart, Nuo Therapeutics ranks #345 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' Days Payable compare to PDSB and LTRN?
According to the Biotechnology industry distribution chart, Nuo Therapeutics ranks #345 out of 704 companies for Days Payable. This puts Nuo Therapeutics in the upper half of its industry. The industry median Days Payable is 113.56. Nuo Therapeutics' value of 82.87 is 27% below this benchmark. Historically, Nuo Therapeutics' own Days Payable has ranged from 109.07 to 8,884.87 over the past decade. While the company's 10-year median is 914.74 vs. the industry median of 113.56, Nuo Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuo Therapeutics's current Days Payable of 82.87 is 27% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nuo Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuo Therapeutics's current Days Payable is 82.87, which is 91% below median its own 10-year median of 914.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.25, compared to a current price of $1.01 — trading 76.2% below its estimated fair value. The current Days Payable is 82.87, which is 91% below median its 10-year median of 914.74 and 27% below the Biotechnology industry median of 113.56. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Days Payable is 82.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nuo Therapeutics (AURX) Overvalued in 2026?
Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued.
The current stock price of $1.01 is trading 76.2% below its estimated GF Value™ of $4.25.
GuruFocus considers Nuo Therapeutics to be Possible Value Trap.
Key valuation signals for AURX:
Days Payable: 82.87 (91% below median its 10-year median of 914.74)
GF Value™: $4.25 vs. price of $1.01 (76.2% below fair value)
Industry Position: 27% below the Biotechnology median (#345 of 704)
No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score
Get the complete analysis for AURX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURX has been successfully added to your 
